Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Yergey

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1993
Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1)D A Nicoll-Griffith, N Chauret, J A Yergey, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 1998
Refinement of an in vitro cell model for cytochrome P450 inductionJ M Silva, P E Morin, S H Day, et al.
Bioorganic & Medicinal Chemistry Letters|May 1, 2001
In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)N Chauret, J A Yergey, C Brideau, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 1993
CYP1A1 specificity of Verlukast epoxidation in mice, rats, rhesus monkeys, and humansS J Grossman, E G Herold, J M Drey, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 22, 2001
Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: leading to structural optimizationC Li, N Chauret, L A Trimble, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 4, 1999
Oxidative bioactivation of the lactol prodrug of a lactone cyclooxygenase-2 inhibitorD A Nicoll-Griffith, J P Falgueyret, J M Silva, et al.
Annals of Neurology|February 1, 1991
Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological statusM P Heyes, B J Brew, A Martin, et al.
Biochemical Pharmacology|October 11, 1996
Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cellsS Kargman, E Wong, G M Greig, et al.
Current Drug Metabolism|July 24, 2001
Enzyme kinetics of cytochrome P450-mediated reactionsM Shou, Y Lin, P Lu, et al.
Journal of Medicinal Chemistry|September 27, 1996
Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stabilityD Delorme, Y Ducharme, C Brideau, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1993
Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1)D A Nicoll-Griffith, N Chauret, J A Yergey, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 1998
Refinement of an in vitro cell model for cytochrome P450 inductionJ M Silva, P E Morin, S H Day, et al.
Bioorganic & Medicinal Chemistry Letters|May 1, 2001
In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)N Chauret, J A Yergey, C Brideau, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 1993
CYP1A1 specificity of Verlukast epoxidation in mice, rats, rhesus monkeys, and humansS J Grossman, E G Herold, J M Drey, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 22, 2001
Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: leading to structural optimizationC Li, N Chauret, L A Trimble, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 4, 1999
Oxidative bioactivation of the lactol prodrug of a lactone cyclooxygenase-2 inhibitorD A Nicoll-Griffith, J P Falgueyret, J M Silva, et al.
Annals of Neurology|February 1, 1991
Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological statusM P Heyes, B J Brew, A Martin, et al.
Biochemical Pharmacology|October 11, 1996
Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cellsS Kargman, E Wong, G M Greig, et al.
Current Drug Metabolism|July 24, 2001
Enzyme kinetics of cytochrome P450-mediated reactionsM Shou, Y Lin, P Lu, et al.
Journal of Medicinal Chemistry|September 27, 1996
Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stabilityD Delorme, Y Ducharme, C Brideau, et al.
Pageof 4